Quotient Sciences, a global integrated CRDMO (contract research, development and manufacturing organization), and Acesion Pharma, a Copenhagen-based biotech company developing treatments for cardiac arrhythmia,  announced a new collaboration applying Quotient Sciences' AI-enhanced formulation development solution within its Translational Pharmaceutics® platform. 

The collaboration supports Acesion's early-stage pipeline of small molecules targeted towards atrial fibrillation, the world's most common sustained cardiac arrhythmia.

The collaboration reflects both companies' shared commitment to advancing innovation in early drug development. Quotient Sciences' AI-enhancedformulation development solution applies active machine learning (ML) with Bayesian optimization to help identify and prioritize the drug products most likely to succeed in the clinic, enabling partners such as Acesion to make faster, better-informed decisions earlier in development.

 Atrial fibrillation: a growing global health challenge

 The lifetime risk of developing atrial fibrillation is approximately one in three adults over age 55, making it one of the most common cardiovascular disorders associated with age.

Patients with atrial fibrillation face an approximately five-fold increased risk of stroke, making effective management critical for reducing serious complications. Atrial fibrillation impacts an estimated 50-60 million people globally.

 AI-enhanced formulation development within Translational Pharmaceutics®

Quotient Sciences' Translational Pharmaceutics® platform optimizes drug development by integrating a range of drug product formulation and clinical activities. It has been used by biotech and pharmaceutical companies globally as a proven method for advancing candidates through early development for more than 20 years.

Now enhanced with Quotient Sciences’ new AI-enhanced formulation development solution, Translational Pharmaceutics® allows development teams to analyze data and predict formulation performance earlier and more precisely, shortening development timelines further while supporting better-informed decisions. Early development activities can be focused on the drug product candidates with the highest chances of clinical success.

 A collaboration built on innovation

 Dr. Andrew Lewis, Chief Scientific Officer at Quotient Sciences, said: “This collaboration with Acesion Pharma reflects exactly what our AI-enhanced formulation development solution, combined with Translational Pharmaceutics®, is designed to deliver: helping our partners make better-informed, faster decisions about their drug product formulations. We're proud to be working with Acesion on a shared commitment to innovation, and to support their pipeline in the field of atrial fibrillation.”

 Dr. Elisabeth V. Carstensen, Vice President CMC, at Acesion Pharma said: “We are excited to, together with Quotient Sciences, explore how their AI-enhanced algorithms can help guide and accelerate oral formulation development for our small-molecule compounds. By helping to guide and accelerate development decisions, this approach has the potential to shorten timelines for clinical testing and increase the likelihood of achieving the desired product profile.”